Fig. 3From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2a Proportion of Delta variant cases from all SARS-CoV-2 PCR positive cases with known S-Gene target information for estimating variant status between 1st May 2021 and 25th June 2021. b Vaccine distribution in Cheshire and Merseyside regionBack to article page